Lercanidipine Approval Status
- FDA approved: No
- Generic name: Lercanidipine
- Company: Forest Laboratories, Inc.
- Treatment for: High Blood Pressure
Lercanidipine is a next generation, long-acting dihydropyridine calcium channel blocker being investigated for the treatment of hypertension.
In August 2002, Forest Laboratories, Inc. received an approvable letter from the FDA seeking additional data related to the proposed dosing regimen. In response to the request, Forest conducted an eight week Phase II pilot study in which approximately 60 patients were dosed once daily with lercanidipine in an experimental modified release formulation. The preliminary study results indicated that this modified release version of lercanidipine was associated with a clinically relevant reduction in blood pressure, but did not meet all the stringent pre-set criteria for dose response across the range of doses studied. Lercanidipine treatment was well tolerated in this study. While lercanidipine is currently available in many countries, it remains commerically undeveloped in the United States.
Development Status and FDA Approval Process for Lercanidipine
|Nov 2, 2004||Forest Laboratories Updates Lercanidipine Development|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.